UNIWERSYTET MEDYCZNY W LODZI

Their core work

The Medical University of Lodz is a Polish medical school with strong clinical and biomedical research capabilities, particularly in chronic disease mechanisms, immune-metabolic disorders, and digital health. Their H2020 work centers on understanding why treatments fail in autoimmune and inflammatory diseases, screening elderly populations for kidney disease, and piloting AI-driven smart hospital systems. They also play an active role in closing the research gap between Central-Eastern and Western European life science institutions through institutional reform initiatives.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), the university focused on capacity building — establishing a centre of excellence for bio-based materials (ICRI-BioM), closing the R&I divide between EU-13 and Western institutions (Alliance4Life), and broad clinical screening (SCOPE). From 2019 onward, the focus shifted sharply toward molecular-level disease understanding: inflammation pathways, autoimmunity treatment response, immune-metabolic causes of comorbidities, and AI-assisted clinical care. This reflects a maturation from institution-building to specialized translational research in precision medicine.

Moving toward data-driven precision medicine — combining immunology, multi-omics, and AI to understand treatment response and disease trajectories in inflammatory and metabolic conditions.

How they like to work

The Medical University of Lodz operates exclusively as a consortium partner — they have never coordinated an H2020 project, which is typical for institutions in EU-13 widening countries building their international research profile. With 218 unique partners across 35 countries, they join large, well-funded consortia rather than leading small teams. This makes them a reliable contributor who brings clinical cohorts and domain expertise without demanding the coordination overhead.

Extensive European network spanning 218 unique partners across 35 countries, built through participation in large multi-site consortia. Their partnerships are spread broadly rather than concentrated in any single geographic cluster, reflecting the pan-European nature of health research projects.

What sets them apart

As a medical university from Central-Eastern Europe, they bring access to clinical populations and healthcare settings that are underrepresented in Western-led consortia — a genuine asset for projects needing diverse patient cohorts. Their dual track in both disease-mechanism research (autoimmunity, inflammation) and digital health (smart hospitals, AI diagnostics) is unusual for a Polish institution of this size. They also understand the EU-13 institutional landscape from the inside, making them a natural bridge for consortia needing partners in the region.

Highlights from their portfolio

• GATEKEEPER
  Their largest single grant (EUR 516,875), deploying smart living home interventions for health-risk populations across Europe — their biggest investment in digital health.
• 3TR
  A long-running project (2019–2026) tackling molecular mechanisms of treatment non-response in autoimmune diseases using single-cell data and integrative genomics — represents their deepest precision medicine commitment.
• TO_AITION
  Investigates the immune-metabolic intersection of cardiovascular disease and depression using biomarkers and inflammation pathways — an unusual and high-value comorbidity angle.